An announcement from Replimune Group Inc (REPL) is now available.
Replimune Group, Inc. has announced a significant reshuffling of its executive team, with Dr. Sushil Patel being named as the new CEO, effective April 1, 2024. This move sees the current CEO, Philip Astley-Sparke, transition to Executive Chairman, while the Board Chair, Dieter Weinand, will take on the role of Lead Independent Director. Additionally, a series of other leadership changes include Dr. Robert Coffin moving to an advisory position and the retirement of COO Dr. Colin Love. These transitions are complemented by the appointments and departures of other executives and are accompanied by detailed employment agreements outlining compensation, benefits, and termination conditions.
See more data about REPL stock on TipRanks’ Stock Analysis page.
